129 related articles for article (PubMed ID: 32984047)
1. Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer.
Marima R; Hull R; Dlamini Z; Penny C
Front Oncol; 2020; 10():1693. PubMed ID: 32984047
[TBL] [Abstract][Full Text] [Related]
2. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.
Marima R; Hull R; Dlamini Z; Penny C
Biomed Pharmacother; 2020 Dec; 132():110829. PubMed ID: 33059259
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines.
Gallego-Escuredo JM; Del Mar Gutierrez M; Diaz-Delfin J; Domingo JC; Mateo MG; Domingo P; Giralt M; Villarroya F
Curr HIV Res; 2010 Oct; 8(7):545-53. PubMed ID: 21073442
[TBL] [Abstract][Full Text] [Related]
6. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
[TBL] [Abstract][Full Text] [Related]
7. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
[TBL] [Abstract][Full Text] [Related]
8. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
9. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz.
Usami Y; Oki T; Nakai M; Sagisaka M; Kaneda T
Chem Pharm Bull (Tokyo); 2003 Jun; 51(6):715-8. PubMed ID: 12808252
[TBL] [Abstract][Full Text] [Related]
10. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Domingo P; Gutierrez Mdel M; Gallego-Escuredo JM; Torres F; Mateo MG; Villarroya J; Lamarca K; Domingo JC; Vidal F; Villarroya F; Giralt M
J Acquir Immune Defic Syndr; 2014 Aug; 66(5):457-65. PubMed ID: 24820106
[TBL] [Abstract][Full Text] [Related]
11. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
13. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
[TBL] [Abstract][Full Text] [Related]
15. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
[TBL] [Abstract][Full Text] [Related]
16. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
17. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
DiCenzo R; Peterson D; Cruttenden K; Morse G; Riggs G; Gelbard H; Schifitto G
Antimicrob Agents Chemother; 2004 Nov; 48(11):4328-31. PubMed ID: 15504860
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China.
Su B; Wang Y; Zhou R; Jiang T; Zhang H; Li Z; Liu A; Shao Y; Hua W; Zhang T; Wu H; He S; Dai L; Sun L
Front Pharmacol; 2019; 10():1472. PubMed ID: 31920659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
